Screening of hepatitis and HIV infections in an alcohol and drug addiction treatment center

Öz

Purpose: Positivity of HBsAg, anti HCV, and anti HIV can expected to be higher in patients treated in an Alcohol and Drug Addiction Treatment Center (ADATC) as they have many risk factors. In this study, screening of these serologic markers in hospitalised patients was aimed.

Material and Methods: A total of 434 patients with a history of alcohol, injecting or noninjecting drug abuse who received treatment in Bursa ADATC unit in 2016 were included in the study. Patient’s files were retrospectively screened for  HBsAg, anti HCV,  anti HIV positivity and demographic features.

Results: Of the 434 patients included in the study  with a mean age of 31.95 ± 11.42 years. HbsAg and anti HCV positivity were 2.8%, and 1.4% respectively. None of the patients had HIV positivity. 59.2% of the patients had a family history of drug use.

Conclusion: It was found that the prevalence of hepatitis B or hepatitis C was higher in the patients who had begun drug use in 9-12 age range, or in the patients who were homeless, who had no social support and living alone. Screening of these infections in ADATC is important for public health which will provide prevention and treatment of these diseases.

Anahtar Kelimeler

• Addiction,HBV,HCV,HIV

Alkol ve uyuşturucu madde bağımlıları tedavi merkezinde hepatit ve HIV enfeksiyonlarının taranması

Öz

Amaç: HBsAg, anti HCV ve anti HIV pozitifliğinin, bir Alkol ve Uyuşturucu Madde Bağımlıları Tedavi Merkezi'nde (AMATEM) tedavi edilen hastalarda, bir çok risk faktörüne sahip olmaları nedeniyle daha yüksek olması beklenebilir. Bu çalışmada, hastanede yatan hastalarda bu serolojik belirteçlerin taranması amaçlandı.

Gereç ve Yöntem: Çalışmaya 2016 yılında Bursa AMATEM ünitesinde yatarak tedavi gören alkol, intravenöz veya intravenöz olmayan  madde bağımlılığı öyküsü olan toplam 434 hasta dahil edildi. Hasta dosyaları geriye dönük olarak HBsAg, anti HCV, anti HIV pozitifliği ve demografik özellikler açısından tarandı

Bulgular: Çalışmaya alınan 434 hastanın ortalama yaşları 31,95 ± 11,42 yıl, HbsAg ve anti HCV pozitifliği ise sırasıyla % 2,8 ve % 1,4 idi. Hastaların hiçbirinde HIV pozitifliği saptanmadı. Hastaların% 59,2'sinde ailede uyuşturucu kullanımı öyküsü vardı.

Sonuç: Hepatit B veya hepatit C prevalansının, 9-12 yaş aralığında madde kullanmaya başlayanlarda veya  evsiz, sosyal destek almayan ve yalnız yaşayan hastalarda yüksek olduğu bulundu. Bu enfeksiyonların AMATEM’de taranması halk sağlığı açısından önemli olup bu hastalıkların önlenmesini ve tedavisini sağlayacaktır.

Anahtar Kelimeler

• Bağımlılık,HBV,HCV,HIV

Kaynakça

1. 1. Basu D, Sharma AK, Gupta S, Nebhinani N, Kumar V. Hepatitis C virus (HCV) infection & risk factors for HCV positivity in injecting & non-injecting drug users attending a de-addiction centre in northern India. The Indian journal of medical research 2015;142:311. https://doi.org/10.4103/0971-5916.166596
2. 2. Mutlu EA, Altıntoprak AE and Tokuçoğlu L. Seroprevalence of hepatitits B, hepatitits C, HIV and syphilis infections among non-injecting drug users. Anadolu Psikiyatri Derg 2015;16:65-68. https://doi.org/10.5455/apd.152522
3. 3. Ruiseñor-Escudero H, Wirtz AL, Berry M, et al. Risky behavior and correlates of HIV and Hepatitis C Virus infection among people who inject drugs in three cities in Afghanistan. Drug & Alcohol Dependence 2014; 143: 127-133. https://doi.org/10.1016/j.drugalcdep.2014.07.022
4. 4. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116
5. 5. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. European journal of epidemiology 2006; 21:299-305. https://doi.org/10.1007/s10654-006-0001-2
6. 6. Evren C, Bilici R, Üçbilek E, İnan D. Türkiye'de damar içi madde kullanan kişilerde hepatit C enfeksiyonunu önlemeye yönelik eylem çağrısı. Dusunen Adam 2017;30:271-277. https://doi.org/10.5350/dajpn20173004001
7. 7. Alaei A, Alaei K, Waye K, et al. Hepatitis C infection and other drug‐related harms among inpatients who injected drugs in Turkey. Journal of viral hepatitis 2017;24:496-505. https://doi.org/10.1111/jvh.12662
8. 8. Mutlu E, Alaei A, Tracy M, Waye K, Cetin MK, Alaei K. Correlates of injection drug use among individuals admitted to public and private drug treatment facilities in Turkey. Drug & Alcohol Dependence 2016;164:71-81. https://doi.org/10.1016/j.drugalcdep.2016.04.032

9. 9. Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World journal of hepatology 2016;8:1295. https://doi.org/10.4254/wjh.v8.i31.1295
10. 10. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. Journal of clinical gastroenterology 2007;41:761-772. https://doi.org/10.1097/mcg.0b013e3180381584
11. 11. Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs and virologic suppression. AIDS care 2017;29:1129-1136. https://doi.org/10.1080/09540121.2017.1327646
12. 12. Mirsal H, Kalyoncu A, Pektas O, Tan D, Beyazyurek M. The prevalance of hepatitis B, C and HIV seropositivity among iv heroin users. J Depend 2003; 4:10-14.
13. 13. Cicek IE, Cicek E, Kayhan F, et al. The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of antidepressant treatment in patients with chronic viral hepatitis: a prospective study. J Psychosom Res 2014;76:227-232. https://doi.org/10.1016/j.jpsychores.2014.01.003
14. 14. Tang LS, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. Jama 2018; 319: 1802-1813. https://doi.org/10.1001/jama.2018.3795
15. 15. Sterling RK, Dharel N. Treatment of hepatitis C, then, now and tomorrow. BMJ Evidence-Based Medicine 2015;20:23-23. https://doi.org/10.1136/ebmed-2014-110103
16. 16. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. Jama 2014;312:631-640. https://doi.org/10.1001/jama.2014.7085
17. 17. Gu W-G. Newly approved integrase inhibitors for clinical treatment of AIDS. Biomedicine & Pharmacotherapy 2014; 68:917-921. https://doi.org/10.1016/j.biopha.2014.09.013
18. 18. Aktaş EÖ, Koçak A, Şenol E, ve ark. Ege Bölgesinde ele geçirilen narkotik maddeler ve madde bağımlılarının incelenmesi. Turkiye Klinikleri Journal of Forensic Medicine and Forensic Sciences 2006;3:13-24.
19. 19. Avşar G, Koç F, Aslan G. Madde bağımlısı hastalarda sosyal destek ve benlik saygısı ACU Sağlık Bil Derg 2016(1):44-49.
20. 20. Yüncü Z, Basay BK, Özbaran B, Aydin C, Tamar M. Madde kullanim bozuklugu olan ergenlerde HBV: Yayginlik, riskler, asilama/Hepatitis B virus among adolescents with substance use disorder: Prevalence, risks, vaccinization. Anadolu Psikiyatri Dergisi 2008;9:208.
21. 21. Yüncü Z, Saatçioğlu H, Aydın C, Özbaran B, Altıntoprak E, Köse S. Bir şehir efsanesi: madde kullanmaya başlama yaşı düşüyor mu. Literatür Sempozyum 2014;1 (4): 43.2014;50.
22. 22. Karakukcu C, Ciraci MZ, Kocer D, Erturk Zararsiz G, Reyhancan M , Altintop I. Regional drug abuse prevalence depending on laboratory based urine illicit drug screening results. Anadolu Psikiyatri Derg 2018;19:169-176. https://doi.org/10.5455/apd.264474
23. 23. Tekin K. Gençlere yönelik güncel tehdit: bonzai Bağımlılığı. Turkiye Klinikleri Journal of Psychiatric Nursing-Special Topics 2015;1:1-5.
24. 24. Karaaziz M, Keskindağ B. Gençler arasındaki popüler psikoaktif madde; sentetik kannabinoid (bonzai): bir gözden geçirme. Klinik Psikiyatri Dergisi 2016;19:137-144. https://doi.org/10.5505/kpd.2016.03522
25. 25. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clinical Microbiology and Infection 2015;21:1020-1026. https://doi.org/10.1016/j.cmi.2015.06.028
26. 26. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. Journal of infection and public health 2016;9:389-395. https://doi.org/10.1016/j.jiph.2015.05.004
27. 27. Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clinical Microbiology and Infection 2016;22:833-838. https://doi.org/10.1016/j.cmi.2016.07.035
28. 28. Gökengin D. Türkiye’de HIV infeksiyonu: hedefe ne kadar yakınız? Klimik Dergisi 2018;31:4-10. https://doi.org/10.5152/kd.2018.04
29. 29. Kandemir Ö, Gültekin O. Kronik hepatit C enfeksiyonlu damar içi uyusturucu madde kullanicilarinda hepatit C virüs genotiplerinin dagilimi/distribution of hepatitis C virus genotypes in injection drug users with chronic hepatitis C. Türkiye Klinikleri. Tip Bilimleri Dergisi 2017;37:21. https://doi.org/10.5336/medsci.2016-54118
30. 30. Duffell EF, Hedrich D, Mardh O, Mozalevskis A. Towards elimination of hepatitis B and C in european union and european economic area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions. Eurosurveillance 2017;22:30476 https://doi.org/10.2807/1560-7917.es.2017.22.9.30476